Evaluation of 5-fluorouracil metabolic enzymes as predictors of response to adjuvant chemotherapy outcomes in patients with stage II/III colorectal cancer: A decision-curve analysis

World Journal of Surgery

Volumn 38, Issue 12, 2014, Pages 3248-3256

  Shigeta, Kohei ^a   Ishii, Yoshiyuki ^b   Hasegawa, Hirotoshi ^a   Okabayashi, Koji ^a   Kitagawa, Yuko ^a  

^a KEIO UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID; MESSENGER RNA; OROTATE PHOSPHORIBOSYLTRANSFERASE; TEGAFUR; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; AGED; COLORECTAL NEOPLASMS; DECISION SUPPORT SYSTEM; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; TUMOR RECURRENCE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DECISION SUPPORT TECHNIQUES; DIHYDROURACIL DEHYDROGENASE (NADP); DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GENE EXPRESSION; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OROTATE PHOSPHORIBOSYLTRANSFERASE; PREDICTIVE VALUE OF TESTS; RNA, MESSENGER; TEGAFUR; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TUMOR MARKERS, BIOLOGICAL;

EID: 84921060287     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-014-2738-1     Document Type: Article

References (36)

1. Scheithauer W, Rosen H, Kornek GV et al (1993) Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 306:752-755
2. Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N Engl J Med 343:905-914
3. Mayer RJ (2000) Moving beyond fluorouracil for colorectal cancer. N Engl J Med 343:963-964
4. de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947
5. Punt CJ (2004) New options and old dilemmas in the treatment of patients with advanced colorectal cancer. Ann Oncol 15:1453-1459
6. Lokich J (1998) Infusional 5-FU: historical evolution, rationale, and clinical experience. Oncology 12:19-22
7. Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330-338
8. Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351
9. Hobday TJ (2005) An overview of approaches to adjuvant therapy for colorectal cancer in the United States. Clin colorectal Cancer 5(Suppl 1):S11-S18
10. Lembersky BC, Wieand HS, Petrelli NJ et al (2006) Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 24:2059-2064
11. Labianca R, Nordlinger B, Beretta GD et al (2010) Primary colon cancer: eSMO clinical practice guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol 21(Suppl 5):v70-v77
12. Twelves C, Wong A, Nowacki MP et al (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352:2696-2704
13. Cascinu S, Aschele C, Barni S et al (1999) Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin Cancer Res 5:1996-1999
14. Leichman CG, Lenz HJ, Leichman L et al (1997) Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15:3223-3229
15. Lenz HJ, Hayashi K, Salonga D et al (1998) p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res 4:1243-1250
16. Paradiso A, Simone G, Petroni S et al (2000) Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 82:560-567
17. Ichikawa W, Uetake H, Shirota Y et al (2003) Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer 89:1486-1492
18. Soong R, Shah N, Salto-Tellez M et al (2008) Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol 19:915-919
19. Boskos CS, Liacos C, Korkolis D et al (2010) Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer. J Surg Oncol 102:408-412
20. Yamada H, Iinuma H, Watanabe T (2008) Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy. Oncol Rep 19:729-735
21. Ikeguchi M, Makino M, Kaibara N (2002) Thymidine phosphorylase and dihydropyrimidine dehydrogenase activity in colorectal carcinoma and patients prognosis. Langenbeck Arch Sur 387:240-245
22. Vignoli M, Nobili S, Napoli C et al (2011) Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil. Pharmacol Res 64:242-248
23. Westra JL, Hollema H, Schaapveld M et al (2005) Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients. Ann Oncol 16:1646-1653
24. Nii A, Shimada M, Ikegami T et al (2009) Significance of dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expressions in hepatocellular carcinoma. Hepatol Res 39:274-281
25. Vickers AJ, Elkin EB (2006) Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 26:565-574
26. Oka H, Ikeda K, Yoshimura H et al (2006) Relationship between p53 status and 5-fluorouracil sensitivity in 3 cell lines. Mutation Res 606:52-60
27. Van Triest B, Pinedo HM, Giaccone G et al (2000) Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Ann Oncol 11:385-391
28. Diasio RB, Lu Z (1994) Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J Clin Oncol 12:2239-2242
29. Sadahiro S, Suzuki T, Tanaka A et al (2012) Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer. Cancer Chemother Pharmacol 70:285-291
30. van Triest B, Pinedo HM, Blaauwgeers JL et al (2000) Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res 6:1063-1072
31. Kumamoto K, Kuwabara K, Tajima Y et al (2012) Thymidylate synthase and thymidine phosphorylase mRNA expression in primary lesions using laser capture microdissection is useful for prediction of the efficacy of FOLFOX treatment in colorectal cancer patients with liver metastasis. Oncol Lett 3:983-989
32. Jensen SA, Vainer B, Witton CJ et al (2008) Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer. Acta Oncol 47:1054-1061
33. Tokunaga Y, Sasaki H, Saito T (2007) Clinical role of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine. Surgery 141:346-353
34. Lassmann S, Hennig M, Rosenberg R et al (2006) Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up. Int J Colorect Dis 21:238-247
35. Donada M, Bonin S, Nardon E et al (2011) Thymidilate synthase expression predicts longer survival in patients with stage II colon cancer treated with 5-flurouracil independently of microsatellite instability. J Cancer Res Clin Oncol 137:201-210
36. Ruckhaberle E, Karn T, Engels K et al (2010) Prognostic impact of thymidine phosphorylase expression in breast cancer-comparison of microarray and immunohistochemical data. Eur J Cancer 46:549-557